US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.14

-0.9799-3.90%

Volume:24.33K

Turnover:594.12K

Market Cap:56.00M

PE:- -

High:25.32

Open:25.32

Low:24.14

Close:25.12

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:1.78

T/O Rate:1.05%

Dividend:1.70

Dividend Rate:7.06%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Alkermes Releases Transcript of Q2 2026 Earnings Call

Alkermes sinks 5% to $50.05 following Q2 report

Relmada Therapeutics Names Bipin Dalmia Chief Business Officer

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

THOMSON REUTERS

Alkermes Q2 Earnings Flat, Revenue Rises; Reiterates 2026 Revenue Guidance

MT Newswires Live

Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints

Alkermes Q2 Sales $496.009M Beat $457.818M Estimate

Benzinga Earnings

Press Release: Alkermes Plc Reports Second Quarter 2026 Financial Results

Alkermes Plc : Piper Sandler Raises Target Price to $65 from $43

THOMSON REUTERS

Greenvale Energy Plans Major Share and Option Issue to Boost Capital Base

Compass Pathways PLC Expected to Post a Loss of 40 Cents a Share - Earnings Preview

Compass Pathways Initiated at Equal-Weight by Wells Fargo

Wells Fargo Initiates COMPASS Pathways at Equalweight

MT Newswires Live

Compass Pathways initiated with an Equal Weight at Wells Fargo

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Celldex (CLDX)

Bristol-Myers Squibb Advances New Lung Cancer Combo Into Phase 2: What Investors Should Watch

Takeda’s Elritercept Trial Targets Anemia in Myelofibrosis, Raising Long-Term Upside for TAK

Jazz Pharmaceuticals Advances Phase 3 Cannabidiol Trial in Severe Childhood Epilepsy

Organon to present results from analysis of Phase 3 trials of VTAMA cream

Radiopharm outlines capital raising plans and risk warnings for oncology radiopharma platform

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/PSIL/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.1401,"timestamp":1789486006146,"preClose":25.12,"halted":0,"volume":24332,"delay":0,"changeRate":-0.03900875796178346,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Trading","change":-0.9799,"latestTime":"09-15 11:27:03 EDT","open":25.3215,"high":25.3215,"low":24.1401,"amount":594120.478336,"amplitude":0.04703,"askPrice":24.24,"askSize":100,"bidPrice":23.91,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":25.12,"sharesOutstanding":1184976,"nav":24.85,"aum":57650992.8,"dividendRate":0.070551,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.12,"preClose":25.12,"latestTime":"19:30 EDT","volume":167,"amount":4194.275,"timestamp":1789428602004,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.78097,"impliedVol":0.4996,"impliedVolPercentile":0.8486},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.78097,"shares":2319976,"dividePrice":1.7031,"high":25.3215,"amplitude":0.04703,"preClose":25.12,"low":24.1401,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.1401,"eps":0,"divideRate":0.070551,"volume":24332,"delay":0,"ttmEps":0,"open":25.3215,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.96,"twentyDayClose":25.83,"sixtyDayClose":20.0904},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654071550","title":"Alkermes Releases Transcript of Q2 2026 Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2654071550","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654071550?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:17","pubTimestamp":1785244649,"startTime":"0","endTime":"0","summary":"Alkermes releases transcript of Q2 2026 earnings callAlkermes discussed Q2 2026 results on an earnings call attended by CEO Richard Pops, CFO Joshua Reed, CCO Todd Nichols, COO and incoming CEO Blair ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL35dZmZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","MEDX","PSCH","BK4139","IBRN","FBT","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007833","title":"Alkermes sinks 5% to $50.05 following Q2 report","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007833","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654007833?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:50","pubTimestamp":1785243027,"startTime":"0","endTime":"0","summary":"08:45 EDT Alkermes (ALKS) sinks 5% to $50.05 following Q2 report Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-sinks-5-to-50-05-following-q2-report-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-sinks-5-to-50-05-following-q2-report-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALKS","IBRN","PSCH","PSIL","MEDX","FBT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654047370","title":"Relmada Therapeutics Names Bipin Dalmia Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654047370","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654047370?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:30","pubTimestamp":1785241852,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics names Bipin Dalmia chief business officerRelmada named Bipin Dalmia as chief business officer, leading corporate strategy, commercial planning, business development; reporting to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDLFbB7t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4007","BK4112","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","SG9999014021.USD","PSIL","IE00BKPKM429.USD","BK4585","BCDF","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","NDAQ","IE00B64PRP62.GBP","SG9999014013.SGD","BK4588","LU2095319765.USD","LU0314104364.USD","RLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654004205","title":"Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654004205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654004205?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:30","pubTimestamp":1785241801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUA1ZDKJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RLMD","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654100907","title":"Alkermes Q2 Earnings Flat, Revenue Rises; Reiterates 2026 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2654100907","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654100907?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:42","pubTimestamp":1785238953,"startTime":"0","endTime":"0","summary":"Alkermes  reported break-even earnings for Q2 Tuesday, compared with earnings of $0.52 per share a year earlier.Analysts polled by FactSet expected a loss of $0.03.Total revenue for the quarter ended June 30 was $496 million, up from $390.7 million a year earlier.Analysts surveyed by FactSet expected $457.4 million.For 2026, Alkermes reiterated its total revenue guidance of $1.73 billion to $1.84 billion. Analysts polled by FactSet expected $1.81 billion.Shares of the company were up less than 1% in recent Tuesday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","FBT","IBRN","ALKS","PSIL","MEDX","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009645","title":"Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009645?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:21","pubTimestamp":1785237677,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals (AVIR) announced topline results from C-BEYOND, its Phase 3 trial conducted in North America evaluating the once-daily fixed-d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atea-pharmaceuticals-reports-c-beyond-trial-meets-primary-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atea-pharmaceuticals-reports-c-beyond-trial-meets-primary-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4007","BBC","AVIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006162","title":"Alkermes Q2 Sales $496.009M Beat $457.818M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006162","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006162?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:02","pubTimestamp":1785236572,"startTime":"0","endTime":"0","summary":"Alkermes (NASDAQ:ALKS) reported quarterly sales of $496.009 million which beat the analyst consensus estimate of $457.818 million by 8.34 percent.  This is a 26.97 percent increase over sales of $390.657 million the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60719288/alkermes-q2-sales-496-009m-beat-457-818m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MEDX","PSIL","PSCH","BK4139","ALKS","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006923","title":"Press Release: Alkermes Plc Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006923","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006923?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:00","pubTimestamp":1785236400,"startTime":"0","endTime":"0","summary":"DUBLIN--(BUSINESS WIRE)--July 28, 2026--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press releas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","PSIL","ADHD","BK4139","MEDX","ALKS","IBRN","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654502005","title":"Alkermes Plc : Piper Sandler Raises Target Price to $65 from $43","url":"https://stock-news.laohu8.com/highlight/detail?id=2654502005","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654502005?lang=en_us&edition=fundamental","pubTime":"2026-07-28 12:05","pubTimestamp":1785211555,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43T1LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","MEDX","ALKS","PSCH","IBRN","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654002919","title":"Greenvale Energy Plans Major Share and Option Issue to Boost Capital Base","url":"https://stock-news.laohu8.com/highlight/detail?id=2654002919","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654002919?lang=en_us&edition=fundamental","pubTime":"2026-07-28 07:50","pubTimestamp":1785196211,"startTime":"0","endTime":"0","summary":"Greenvale Mining ( ($AU:GRV) ) has provided an update. Greenvale Energy Ltd has notified the ASX of a proposed capital raising via a placement and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/greenvale-energy-plans-major-share-and-option-issue-to-boost-capital-base?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/greenvale-energy-plans-major-share-and-option-issue-to-boost-capital-base?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654436048","title":"Compass Pathways PLC Expected to Post a Loss of 40 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2654436048","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654436048?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:03","pubTimestamp":1785157388,"startTime":"0","endTime":"0","summary":"Compass Pathways PLC <CMPS.OQ> expected to post a loss of40cents a share - Earnings PreviewCompass Pathways PLCCMPS.OQCMPS.Ois expected to  show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL8N43T154:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654485310","title":"Compass Pathways Initiated at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2654485310","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654485310?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:52","pubTimestamp":1785156720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings(END) Dow Jones NewswiresJuly 27, 2026 08:52 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTXO","LU0310799852.SGD","LU2361044949.HKD","LU0708994859.HKD","LU0477156953.USD","KBWB","LU0683600562.USD","LU1894683348.USD","PSIL","LU0310800379.SGD","IYF","LU0251142724.SGD","LU0048573561.USD","LU0314106906.USD","LU0251131958.USD","CMPS","LU0289960550.SGD","LU0128525929.USD","LU1069347547.HKD","TFNS","LU0130517989.USD","LU1267930227.SGD","LU0052756011.USD","LU0072461881.USD","LU2361044865.SGD","LU0648001328.SGD","LU1267930490.SGD","IE0002270589.USD","LU1506573853.SGD","LU0417517546.SGD","PGF","LU0070302665.USD","LU0980610538.SGD","BK4501","LU2361045086.USD","LU0029864427.USD","LU1668664300.SGD","LU1791807156.HKD","BK4139","BK4582","BK4585","IE00B19Z3581.USD","LU0971096721.USD","LU0868494708.USD","LU1280957306.USD","LU0256863811.USD","LU0128525689.USD","LU0208291251.USD","IE000M9KFDE8.USD","LU1201861249.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654017757","title":"Wells Fargo Initiates COMPASS Pathways at Equalweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017757","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654017757?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:12","pubTimestamp":1785154373,"startTime":"0","endTime":"0","summary":"COMPASS Pathways (CMPS) has an average rating of buy and mean price target of $22.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0106831901.USD","LU0048573561.USD","LU1894683264.USD","PSIL","LU0708994859.HKD","CMPS","LU0211328371.USD","LU0267386448.USD","LU1280957306.USD","FTXO","BK4585","LU0648001328.SGD","PGF","LU1267930573.SGD","LU2361044949.HKD","LU2236285917.USD","LU1069347547.HKD","BK4207","LU0052756011.USD","LU0683600562.USD","LU2461242641.AUD","LU0162691827.USD","LU0787776722.HKD","LU0310800965.SGD","BK4139","LU0320765489.SGD","LU1814569148.SGD","LU2361044865.SGD","LU0211327993.USD","LU1791807156.HKD","LU1506573853.SGD","LU1074936037.SGD","LU0128525929.USD","IYF","BK4501","WFC","LU1201861249.SGD","LU2361045086.USD","LU0417517546.SGD","TFNS","LU0072461881.USD","LU0868494617.USD","BK4588","LU0251142724.SGD","KBWB","LU0070302665.USD","BK4559","LU0130102774.USD","LU0314106906.USD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654016997","title":"Compass Pathways initiated with an Equal Weight at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2654016997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654016997?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:25","pubTimestamp":1785144306,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Benjamin Burnett initiated coverage of Compass Pathways (CMPS) with an Equal Weight rating and $13 price target While the two p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-pathways-initiated-with-an-equal-weight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-pathways-initiated-with-an-equal-weight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2361045086.USD","LU0130102774.USD","FTXO","LU2361044865.SGD","LU1668664300.SGD","LU0211328371.USD","LU0314106906.USD","IE0002270589.USD","LU0640476718.USD","KBWB","LU0256863811.USD","LU0310800379.SGD","LU0048573561.USD","LU1267930573.SGD","LU1035773651.USD","LU1069347547.HKD","LU1791807156.HKD","PGF","LU1894683264.USD","LU1074936037.SGD","LU2236285917.USD","BK4501","BK4139","TFNS","CMPS","IE000M9KFDE8.USD","LU0251142724.SGD","LU1363072403.SGD","LU1201861249.SGD","LU0417517546.SGD","IE00B19Z3581.USD","LU0175139822.USD","BK4582","BK4559","PSIL","BK4207","LU0942090050.USD","LU0683600562.USD","LU1267930490.SGD","LU1267930227.SGD","LU0742534661.SGD","LU0072461881.USD","LU0029864427.USD","LU1894683348.USD","BK4585","LU2461242641.AUD","LU0971096721.USD","IYF","LU0310799852.SGD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654054554","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654054554","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654054554?lang=en_us&edition=fundamental","pubTime":"2026-07-25 22:50","pubTimestamp":1784991019,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Celldex (CLDX) with bullish sent...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XLV","BK4581","BK4588","LU0128526141.USD","XBI","BK4585","PSIL","ALKS","LU0029874061.USD","BK4139","MEDX","BK4137","FBT","HCSG","PSCH","CLDX","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036222","title":"Bristol-Myers Squibb Advances New Lung Cancer Combo Into Phase 2: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036222?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:34","pubTimestamp":1784910898,"startTime":"0","endTime":"0","summary":"Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb is running a Phase 2 trial to test a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bristol-myers-squibb-advances-new-lung-cancer-combo-into-phase-2-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bristol-myers-squibb-advances-new-lung-cancer-combo-into-phase-2-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","LU1261432733.SGD","LU0882574055.USD","BMY","LU0321505868.SGD","LU0225771236.USD","LU1670710588.SGD","LU0306807586.USD","IE00BFTCPJ56.SGD","LU0267386448.USD","BK4007","LU0306806265.USD","LU0321505439.SGD","IE00BJJMRZ35.SGD","BK4581","LU1291159041.SGD","LU0061475181.USD","LU1868836757.USD","IE00BFXG1179.USD","LU1670710661.SGD","LU2125154778.USD","PSIL","IE00B2B36J28.USD","LU0456855351.SGD","IHE","IE00BSNM7G36.USD","BK4532","LU1868837136.USD","LU2125154935.USD","LU2242646821.SGD","BK4211","LU1983299246.USD","BK4588","BK4534","LU1585245621.USD","LU1670711040.USD","ISBC","LU0114720955.EUR","LU0432979614.USD","BBC","LU1323610961.USD","FTXH","LU1868836591.USD","LU0225284248.USD","BK4585","LU0985481810.HKD","LU1093756325.SGD","LU0237698245.USD","LU1868836914.USD","LU1074936037.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654362520","title":"Takeda’s Elritercept Trial Targets Anemia in Myelofibrosis, Raising Long-Term Upside for TAK","url":"https://stock-news.laohu8.com/highlight/detail?id=2654362520","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654362520?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:34","pubTimestamp":1784910878,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Takeda is running a Phase 3 trial to test elritercept (TA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takedas-elritercept-trial-targets-anemia-in-myelofibrosis-raising-long-term-upside-for-tak?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takedas-elritercept-trial-targets-anemia-in-myelofibrosis-raising-long-term-upside-for-tak?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TAK","PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036255","title":"Jazz Pharmaceuticals Advances Phase 3 Cannabidiol Trial in Severe Childhood Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036255","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036255?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:33","pubTimestamp":1784910829,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals ($JAZZ) announced an update on their ongoing clinical study. Jazz Pharmaceuticals is preparing a Phase 3 trial to test a new o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jazz-pharmaceuticals-advances-phase-3-cannabidiol-trial-in-severe-childhood-epilepsy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jazz-pharmaceuticals-advances-phase-3-cannabidiol-trial-in-severe-childhood-epilepsy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653204084","title":"Organon to present results from analysis of Phase 3 trials of VTAMA cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2653204084","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653204084?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:11","pubTimestamp":1784895078,"startTime":"0","endTime":"0","summary":"Organon (OGN) will present results from a post hoc analysis of pooled data from the Phase 3 pivotal trials, ADORING 1 and ADORING 2, evaluating the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/organon-to-present-results-from-analysis-of-phase-3-trials-of-vtama-cream-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/organon-to-present-results-from-analysis-of-phase-3-trials-of-vtama-cream-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065170008.USD","OGN","LU2065171402.SGD","BK4585","BK4559","PSIL","BK4588","LU2065171311.SGD","FXH","BK4007","LU2065169927.USD","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653702156","title":"Radiopharm outlines capital raising plans and risk warnings for oncology radiopharma platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2653702156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653702156?lang=en_us&edition=fundamental","pubTime":"2026-07-24 15:38","pubTimestamp":1784878698,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Radiopharm Theranostics Limited ( ($AU:RAD) ). Radiopharm Theranostics has released a capital raising presentat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/radiopharm-outlines-capital-raising-plans-and-risk-warnings-for-oncology-radiopharma-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/radiopharm-outlines-capital-raising-plans-and-risk-warnings-for-oncology-radiopharma-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}